(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Psychiatry Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets's offering.
Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of 569 psychiatry deals from 2019 to 2025. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. The chapters cover various aspects of the deals: Chapter 1 offers an introduction, Chapter 2 analyzes trends, Chapter 3 details financial terms, Chapter 4 reviews top companies in psychiatry dealmaking, Chapter 5 examines deals with available contracts, and Chapter 6 lists deals by therapeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse psychiatry collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in psychiatry dealmaking
2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Psychiatry partnering by deal type
2.4. Psychiatry partnering by industry sector
2.5. Psychiatry partnering by stage of development
2.6. Psychiatry partnering by technology type
2.7. Psychiatry partnering by therapeutic indication
Chapter 3 - Financial deal terms for psychiatry partnering
3.1. Introduction
3.2. Disclosed financials terms for psychiatry partnering
3.3. Psychiatry partnering headline values
3.4. Psychiatry deal upfront payments
3.5. Psychiatry deal milestone payments
3.6. Psychiatry royalty rates
Chapter 4 - Leading psychiatry deals and dealmakers
4.1. Introduction
4.2. Most active in psychiatry partnering
4.3. List of most active dealmakers in psychiatry
4.4. Top psychiatry deals by value
Chapter 5 - Psychiatry contract document directory
5.1. Introduction
5.2. Psychiatry partnering deals where contract document available
Chapter 6 - Psychiatry dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by psychiatry therapeutic target

Companies Featured

• Zurich
• Boston Scientific
• Fujifilm
• Quanterix
• BioNTech
• Eli Lilly
• Teva Pharmaceutical Industries
• Alkermes
• Amgen
• Genentech
• Novartis
• Vertex Pharmaceuticals
• Gilead Sciences
• Moderna
• UCB
• Baxter
• Incyte
• Sanofi
• Merck & Co
• Bristol-Myers Squibb
• Johnson & Johnson
• Pfizer
• AstraZeneca
• Abbott
• Roche
• Takeda Pharmaceutical
• GSK
• Bayer
• Nasdaq
• Tesla
• Intel
• Facebook
• Amazon
• Microsoft
• Apple
• Google
• Disney
• Netflix
• PayPal
• Square
• Mastercard
• Visa
• American Express
• Nintendo
• Adobe
• NVIDIA
• AMD
• Samsung
• LG
• Xerox
• Cisco

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112025004107003653ID1110368295